| Basics |
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders.
|
| IPO Date: |
October 5, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$6.78B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.78 | 2.94%
|
| Avg Daily Range (30 D): |
$1.61 | 1.70%
|
| Avg Daily Range (90 D): |
$1.52 | 2.01%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.4M |
| Avg Daily Volume (30 D): |
.44M |
| Avg Daily Volume (90 D): |
.55M |
| Trade Size |
| Avg Trade Size (Sh.): |
70 |
| Avg Trade Size (Sh.) (30 D): |
36 |
| Avg Trade Size (Sh.) (90 D): |
43 |
| Institutional Trades |
| Total Inst.Trades: |
2,609 |
| Avg Inst. Trade: |
$2.35M |
| Avg Inst. Trade (30 D): |
$5.21M |
| Avg Inst. Trade (90 D): |
$3.93M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.24M |
| Avg Closing Trade (30 D): |
$8.27M |
| Avg Closing Trade (90 D): |
$6.78M |
| Avg Closing Volume: |
100.43K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-3.01
|
$-.75
|
$-.81
|
|
Diluted EPS
|
$-3.01
|
$-.75
|
$-.81
|
|
Revenue
|
$ 156.29M
|
$ 48.5M
|
$ 32.7M
|
|
Gross Profit
|
$ 139.48M
|
$ 42.96M
|
$ 29.06M
|
|
Net Income / Loss
|
$ -183.06M
|
$ -46.63M
|
$ -49.5M
|
|
Operating Income / Loss
|
$ -177.44M
|
$ -45.3M
|
$ -47M
|
|
Cost of Revenue
|
$ 16.81M
|
$ 5.54M
|
$ 3.65M
|
|
Net Cash Flow
|
$ -26.11M
|
$ 29.83M
|
$ 16.96M
|
|
PE Ratio
|
|
|
|
|
|
|
